PAMAfrica

Portfolio approach to developing the next-generation of malaria treatments for Africa

This project is part of the EDCTP2 Programme supported by the European Union.
EDCTP
EU

Search

Search

  • About us
    • What we do
    • Governance
    • PAMAfrica scientists
    • PAMAfrica students
  • Work packages
    • Next-generation drug combination for uncomplicated malaria
    • First malaria treatment for babies under 5kg
    • New medicine for treatement of severe malaria
    • Building research capacity
  • Consortium partners
  • Newsroom
    • Resources
    • News
Search
In-person PAMAfrica & SINDOFO back-to-back annual meetings

Read more 

Meet 2021 PAMAfrica students

Watch a short video here

 

Read the report of the first Annual PAMAfrica Consortium Meeting 

Read more 

Interview with Alberto Chauque - One of PAMAfrica’s MSc students

Read more

Interview with Victor Asua - One of PAMAfrica’s PhD students

Read more

First PAMAfrica MSc student at Witwatersrand University

Read more

First PAMAfrica student selected for an MSc program

Read more

Dr Halidou Tinto elected Fellow of the African Academy of Sciences

Read more

Photo: Dr Tinto – ©IT CRUN

Take a look at our infographic!

Read more

Photo: Damien Schumann

Read EDCTP's interview with Dr Tim Wells, Chief Scientific Officer of MMV

Read more

Photo: BrianAJackson/iStock

Take a look at our infosheet!

Read more

Photo: Alex Radelich

Portfolio approach to developing the next-generation of malaria treatments for Africa

1

Work packages

Next-generation drug combination for uncomplicated malaria

First malaria treatment for babies under 5kg

New medicine for treatment of severe malaria

Building research capacity in Africa

1

PAMAfrica scientists

Dr Yeka Adoke

Ph.D, Director and Principal Investigator at IDRC (WP 1)

Miss Sarita Barsainya

Masters in Pharmacy, Global Trial Director at Novartis (WP 3)

Dr Quique Bassat

PhD, Head of the Malaria Programme at ISGlobal (WP 2)

Dr Helen Demarest

PhD, Director, Clinical Operations for MMV (WP 4)

Dr Ghyslain Mombo-Ngoma

MD, PhD, Head of Clinical Operations at CERMEL (WP 1 - WP 3)
View more profiles of our scientists

Consortium Partners

MMV

Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in antimalarial drug research in its 20th year.

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. 

Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics.

Tubingen logo

The Eberhard Karls Universität Tübingen

The Eberhard Karls Universität Tübingen is one of Europe’s oldest universities, with key strengths in Sciences and Life Sciences. Within the Faculty of Medicine, the Institute of Tropical Medicine (ITM) is an established Centre of Excellence (since 2007).

CERMEL

ISGlobal logo

ISGlobal

The ultimate goal of ISGlobal is to help close the gaps in health disparities between and within different regions of the world.

Manhiça Health Research Centre

Manhiça Health Research Centre is a research institution managed by Manhiça Foundation, whose mission is to promote and conduct biomedical research in health priority areas to promote and safeguard the health of the population.

Groupe de Recherche Action en Santé logo

GRAS

The Groupe de Recherche Action en Santé (GRAS) is a private institute based in Burkina Faso, operating since 2008 in the field of health research.

IDRC

IDRC conducts research in infectious diseases including Malaria, HIV, Tuberculosis and other diseases of public health importance through collaboration and partnership. 

CRUN

The CRUN’s mission is to provide evidence-based information for the health care of populations living in tropical countries. 

1

Resources

20 Oct 2022

PAMAfrica and SINDOFO annual meeting report

The PAMAfrica & SINDOFO back-to-back annual meetings took place at CERMEL’s facility in Lambaréné, Gabon from 20 to 22 September. The objective was to share progress and future plans per work package, with discussions on selected topics.

Article
10 Nov 2021

Meet PAMAfrica students

Audio/Video
01 Nov 2021

Report - 1st Annual PAMAfrica Consortium meeting

Article
Photo: AJackson/iStock
26 Oct 2021

Safety, pharmacokinetics, and antimalarial activity of the novel plasmodiumeukaryotic translation elongation factor 2 inhibitor M5717

A first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. 

The Lancet Infectious Diseases
Peer-reviewed article
View all

Contact us

infopamafrica [at] mmv [dot] org

A Remora website by Manta Ray Media